<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cutaneous leishmaniasis: Clinical manifestations and diagnosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cutaneous leishmaniasis: Clinical manifestations and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Cutaneous leishmaniasis: Clinical manifestations and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Naomi Aronson, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter F Weller, MD, MACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Milana Bogorodskaya, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 14, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H83446430"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Leishmaniasis consists of a complex of vector-borne diseases caused by a heterogeneous group of protozoa belonging to the genus <em>Leishmania</em>; it is transmitted by sand fly vectors [<a href="#rid1">1</a>]. Clinical manifestations range from cutaneous ulcers to systemic multiorgan disease. Specific organisms are frequently associated with a typical clinical picture  (<a class="graphic graphic_table graphicRef86988" href="/z/d/graphic/86988.html" rel="external">table 1</a>), although this can be variable.</p><p>The clinical manifestations and diagnosis of cutaneous leishmaniasis (CL) will be reviewed here. Issues concerning treatment, epidemiology, and control are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5686.html" rel="external">"Cutaneous leishmaniasis: Treatment"</a> and  <a class="medical medical_review" href="/z/d/html/87186.html" rel="external">"Cutaneous leishmaniasis: Epidemiology and control"</a>.)</p><p class="headingAnchor" id="H83446472"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>The incubation period for symptomatic CL ranges from weeks to months; mucosal involvement may occur years following initial infection [<a href="#rid2">2-4</a>]. Asymptomatic infection may occur in about 10 percent of patients; this has been suggested by delayed hypersensitivity skin testing [<a href="#rid5">5</a>].</p><p><em>Leishmania</em> causes a spectrum of cutaneous disease. The range of clinical manifestations may be attributed to variability in parasite virulence (and other intrinsic characteristics) and variability in the host immune response. At one end of the spectrum, mucosal leishmaniasis (ML) and leishmaniasis recidivans (LR) are caused by oligoparasitic disease associated with a marked cellular immune response. The center of the spectrum consists of localized cutaneous leishmaniasis (LCL), which is the most common clinical presentation. At the opposite end of the spectrum, diffuse cutaneous leishmaniasis (DCL) is caused by polyparasitic disease with a predominance of parasitized macrophages and no granulomatous inflammation. This spectrum of clinical presentation and host immune response is similar to clinical manifestations observed in the setting of leprosy [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/z/d/html/5348.html" rel="external">"Leprosy: Epidemiology, microbiology, clinical manifestations, and diagnosis"</a>.)</p><p>The cutaneous syndromes associated with <em>Leishmania</em> parasite infection include LCL, LR, DCL, and ML. These will be further described below; they are presented in order of relative clinical frequency.</p><p class="headingAnchor" id="H83446480"><span class="h2">Localized cutaneous leishmaniasis</span><span class="headingEndMark"> — </span>Cutaneous lesions tend to occur on exposed areas of the skin; sand fly mouthparts generally cannot penetrate through clothing. Sand fly bite reactions are generally pruritic but usually do not enlarge; they may resolve slowly over weeks (even in the absence of parasitic infection).</p><p>Localized cutaneous leishmaniasis (LCL) begins as a pink-colored papule that enlarges and develops into a nodule or plaque-like lesion (often with central softening), leading to a painless ulceration with an indurated border  (<a class="graphic graphic_picture graphicRef64620" href="/z/d/graphic/64620.html" rel="external">picture 1</a>). In Old World CL, the ulcer is often covered with a hyperkeratotic eschar  (<a class="graphic graphic_picture graphicRef87207" href="/z/d/graphic/87207.html" rel="external">picture 2</a>). In New World CL, the ulcer may be covered with thick white-yellow fibrinous material  (<a class="graphic graphic_picture graphicRef86992" href="/z/d/graphic/86992.html" rel="external">picture 3</a>).</p><p>Multiple lesions may be present. The clinical appearance can be variable and may include sporotrichoid, verrucous, zosteriform, psoriaform, eczematous, and/or erysipeloid features [<a href="#rid7">7</a>]. Small satellite lesions may develop just outside the plaque/ulcer. Spread of lesions along the draining lymphatics may be observed; these may or may not ulcerate but can be palpated subcutaneously and proximally along the lymphatic chain leading from the primary lesion (nodular lymphangitis). Regional adenopathy can occur and may be prominent in some cases [<a href="#rid8">8</a>].</p><p>Secondary bacterial infection of the ulcer may occur and may be associated with purulent drainage and local cellulitis. Bacterial superinfection may lead to enlargement of the primary lesion and contribute to its persistence.</p><p>The natural history of LCL consists of gradual healing over months to years; the time varies depending on the species and lesion size [<a href="#rid7">7,9</a>]. Leishmaniasis heals with an atrophic, depressed scar; it can also heal as a keloid (in patients predisposed to keloid scarring). Following resolution of the initial lesion(s), it is possible that reactivation of the initial lesion(s) may develop during the subsequent year (or later for ML).</p><p>There are some distinguishing clinical features between species, although significant overlap may occur; speciation should not be based solely on clinical manifestations.</p><p class="bulletIndent1"><span class="glyph">●</span><em>L.L. major</em> infection (Old World CL) typically has a short incubation period, and ulcers may expand in one to two months to ≥6 cm in diameter. Multiple lesions are common. Frequently, ulcers are covered with a thick crust, and nodular, plaque-like lesions are common. Epithelialization of the ulcer bed usually occurs within six months.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>L.L. tropica</em> infection (Old World CL) is typically a more chronic infection than CL due to <em>L.L. major</em>; it evolves over months to years. The skin lesions are relatively few in number and sometimes relatively small (1 to 2 cm). Facial lesions may be larger, and a predilection for the nose and forehead may be observed. The lesions are very dry and appear crusted. Spontaneous resolution is slow, usually over one to two years or longer. <em>L.L. tropica</em> can be associated with the complication of LR. (See <a class="local">'Leishmaniasis recidivans'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>L.L. aethiopica</em> infection (Old World CL) usually consists of a solitary facial lesion with or without surrounding satellite papules, which coalesce into spreading nodules or plaques. Lesions may spread along mucocutaneous margins but do not involve the oral or nasal mucosa. <em>L.L. aethiopica</em> is associated with relatively long chronicity. Histologically, relatively little inflammation is seen.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>L.L. infantum-chagasi</em> infection can cause a small number of slow-growing nodular lesions that persist for years. This is an Old and New World species most often associated with visceral leishmaniasis, but it can also cause CL; its presence in the skin does not imply coexistent visceral disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>L.L. mexicana</em> (New World CL) infection generally produces small, chronic skin ulcers, usually one or few in number. Lesions on the ear are called "Chiclero's ulcer," which reflects the biting habits of the sand fly vector. <em>L.L. mexicana</em> lesions may spontaneously heal relatively quickly; one study noted 88 percent of lesions healed by 14 weeks [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>L.V. braziliensis</em> (New World CL) infection causes large lesions, frequently with lymphocutaneous involvement. A sporotrichoid pattern of multiple ulcers or nodular lymphangitis is common  (<a class="graphic graphic_picture graphicRef64620" href="/z/d/graphic/64620.html" rel="external">picture 1</a>). Lymphadenopathy, fever, and malaise may precede development of any lesion [<a href="#rid10">10</a>]. Ulcers may heal in 6 to 12 months but can be quite persistent [<a href="#rid11">11</a>]. <em>L.V. braziliensis</em> CL may be associated with mucosal leishmaniasis concurrently or subsequently. Disseminated CL due to <em>L.V. braziliensis</em> appears to be emerging in northeast Brazil [<a href="#rid12">12</a>].</p><p></p><p class="headingAnchor" id="H1961622"><span class="h3">Differential diagnosis</span><span class="headingEndMark"> — </span>The differential diagnosis of LCL includes bacterial infection, cutaneous myiasis, pyoderma gangrenosum, ecthyma, impetigo, cutaneous malignancy, sarcoidosis, prurigo nodularis, lichen simplex chronicus, spider bite, tropical ulcer, yaws, cutaneous anthrax, nocardia and actinomycosis, cutaneous tuberculosis, nontuberculous mycobacteria such as <em>Mycobacterium marinum</em>, <em>M. fortuitum</em>, and less likely Buruli ulcer (<em>M. ulcerans</em>), and fungal infections such as sporotrichosis, blastomycosis, and chromoblastomycosis.</p><p>Clinical features that may help differentiate CL from these entities include its chronicity, general painlessness, frequent clustering of lesions, occurrence on an exposed location, and orientation of skin lesion along skin creases. Other important distinguishing characteristics include the presence of inflammatory satellite papules, subcutaneous induration beneath lesion, ulcerations with well-defined indurated borders, and presence of subcutaneous nodules [<a href="#rid13">13</a>].</p><p>Epidemiologic clues that may suggest leishmaniasis include that most individuals with leishmaniasis are otherwise healthy, cases may cluster (several individuals in an exposed group may have skin lesions), some patients recall small insect bites, exposure is usually in rural areas dusk to dawn during the warmer months, risk is usually recent travel or residence in leishmaniasis-endemic regions, and incubation period is typically several weeks to a few months.</p><p>Minor trauma with exposure to brackish water suggests <em>M. marinum</em>. Persistent pruritus is consistent with the chronic sequelae of insect bites. Initial minor skin trauma on extremities in gardeners or farmers is suggestive of sporotrichosis. Animal-to-human transmission of sporotrichosis can occur via chronic ulcerative lesions. Wood cutters with no footwear in tropical forests with high rainfall in South America and Madagascar are at risk for chromoblastomycosis. Immunocompromised hosts may have cutaneous tuberculosis or rapid-growing nontuberculous mycobacterial skin lesions.</p><p class="headingAnchor" id="H83446505"><span class="h2">Leishmaniasis recidivans</span><span class="headingEndMark"> — </span>Leishmaniasis recidivans (LR) refers to a relatively uncommon syndrome caused by <em>L.L. tropica</em> infection. Following healing of the primary lesion, persistent organisms can cause new papules to form around the margin of the scar. Skin biopsy demonstrates few parasites but a robust granulomatous, cell-mediated immune response. LR can occur following trauma in the area of a prior lesion many years after initial healing [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H83446520"><span class="h2">Diffuse cutaneous leishmaniasis</span><span class="headingEndMark"> — </span>Diffuse cutaneous leishmaniasis (DCL) is a rare syndrome that occurs mainly in the setting of <em>L.L. aethiopica</em>, <em>L.L. mexicana</em>, and <em>L.L. amazonensis</em> infection. It begins as a localized lesion that does not ulcerate; rather, amastigotes disseminate to macrophages in other areas of the skin. In general, soft nodules or plaques form on the face and extensor limb surfaces, but the entire body may be involved. Histologically, many parasites are seen, but there is scarce lymphocytic reaction. Patients with DCL usually have a defect in the cell-mediated immune response and are anergic to <em>Leishmania</em> antigen. DCL due to <em>L.L aethiopica</em> is associated with high rates of ML [<a href="#rid15">15</a>]. DCL reported in acquired immunodeficiency syndrome (AIDS) patients has involved other parasites species such as <em>L.L. major</em> and <em>L.V. guyanensis</em> [<a href="#rid16">16</a>]. Successful treatment of DCL is difficult.</p><p class="headingAnchor" id="H83446528"><span class="h2">Mucosal leishmaniasis</span><span class="headingEndMark"> — </span>Mucosal leishmaniasis (ML), also known as espundia, occurs in the New World and is caused by the <em>Viannia </em>subgenus, especially <em>L.V. braziliensis</em>, <em>L.V. guyanensis</em>, and <em>L.V. panamensis</em>, but also <em>L.L. amazonensis </em> (<a class="graphic graphic_figure graphicRef110869" href="/z/d/graphic/110869.html" rel="external">figure 1</a>) [<a href="#rid17">17</a>]. ML due to Old World species <em>L.L. infantum</em> and <em>L.L. aethiopica</em> has been described among immunocompromised hosts (see <a class="local">'CL in immunocompromised hosts'</a> below). Rarely, <em>L.L. tropica</em>, <em>L.L. major</em>, <em>L.L donovani,</em> and <em>L.L. infantum-chagasi</em> mucosal leishmaniasis are reported [<a href="#rid18">18,19</a>].</p><p>The risk of ML due to <em>L.V. braziliensis</em> infection is higher in South America (particularly Bolivia, Peru, and Brazil) than in Central America, specifically north of Costa Rica. Overall, the risk of mucosal disease following a primary CL lesion is less than 10 percent; in some reports, it has been close to 30 percent [<a href="#rid20">20</a>]. ML can occur concurrently or following partially treated or untreated CL. Concurrent ML has been described in up to 28 percent of cases; subsequent ML can occur up to 10 years or more following CL [<a href="#rid21">21</a>].</p><p>ML is characterized by mucosal destruction. Symptoms include nasal stuffiness or blockage, mucosal bleeding, increased secretions, and sloughing of dead tissue. Some have pain, deformity, and inflammation  (<a class="graphic graphic_picture graphicRef86914" href="/z/d/graphic/86914.html" rel="external">picture 4</a>). Erosion of mucosal surfaces occurs, most commonly in the nose, mouth, or nasal septum (eg, in the form of cartilage perforation). Other involved areas may include the cheek, pharynx, palate, epiglottis, larynx, trachea, and genitalia. Hoarseness and/or a brassy cough are suggestive of laryngeal involvement. The disease is considered mild in the setting of isolated nasal stuffiness, moderate if there is associated odynophagia or dysphonia, and severe if there is respiratory distress or severe dysphonia.</p><p>Substantial disfigurement can result from destruction of the nasal cartilage and surrounding tissues. Rarely, aspiration, respiratory compromise, and/or death can occur. Any patient with New World CL (<em>Viannia</em> subgenus) regardless of nasal, oral, or hypopharyngeal symptoms should undergo visual inspection of all mucosal surfaces of the hypopharynx, including the vocal cords and oronasal pharynx. Abnormal-appearing tissue should be biopsied, and histopathology as well as polymerase chain reaction (PCR) testing for <em>Leishmania</em> should be performed.</p><p>Histopathology generally demonstrates a robust cell-mediated immune response, and large quantities of cytokine production, T lymphocyte proliferation, and neutrophils expressing proteinases have been observed [<a href="#rid22">22</a>]. In general, relatively few parasites are observed in mucosal lesions.</p><p><em>Leishmania</em> RNA virus 1 (LRV1), an endosymbiont of <em>L.V. guyanensis</em> and some <em>L.V. braziliensis</em> organisms, may augment infection and may also be associated with metastatic involvement. It acts as an immunogen and elicits a hyperinflammatory immune response through toll-like receptor 3 (TLR3) [<a href="#rid23">23</a>].</p><p class="headingAnchor" id="H83446544"><span class="h2">CL in immunocompromised hosts</span><span class="headingEndMark"> — </span>Control of intracellular <em>Leishmania</em> infection requires a Th1-dependent cell-mediated immune response including cells (CD4 and CD8 T cells, natural killer, dendritic cells, macrophages) and cytokines (interferon-gamma, tumor necrosis factor-alpha, interleukin-12).</p><p>Patients with immunosuppressing conditions are at increased risk for more severe cutaneous leishmaniasis (CL). This includes patients on chronic corticosteroids, biologic modulators, or other immunosuppressive drugs; organ transplant recipients; pregnant patients; and patients with HIV/AIDS:</p><p class="bulletIndent1"><span class="glyph">●</span>Reactivation of CL and dissemination or progression to ML has been noted after chronic corticosteroid use. It has also been observed that application of topical steroids to CL lesions leads to increased numbers of amastigotes on skin biopsy, suggesting that corticosteroids may contribute to local disruption of immune regulation [<a href="#rid24">24,25</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Biologic immunomodulators (such as <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a>) have been associated with both primary and reactivation CL [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CL is relatively unusual among organ transplant recipients; it has been observed in the Mediterranean region with onset long after transplant (median 18 months, range 6 to 19 months) [<a href="#rid27">27</a>]. Other relatively unusual observations include a case of DCL due to <em>L.L. major</em> (a species not usually associated with dissemination outside the skin) and some CL cases with multiple lesions consisting of nodular rather than ulcerative appearance [<a href="#rid27">27,28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>HIV-induced immunosuppression has been associated with CL primary infection as well as reactivation, since <em>Leishmania</em> parasites are capable of persisting in scars of prior lesions [<a href="#rid29">29</a>]. CL in patients with HIV/AIDS has also been associated with disseminated disease, especially in the setting of CD4 &lt;200/mm³. Manifestations include disseminated CL due to <em>L.L. major</em>, rapid progression of New World CL to ML, and ML due to <em>L.L. infantum-chagasi</em>. Patients with AIDS may be less responsive to treatment than other patients and may require therapy for suppression of CL infection until immune reconstitution occurs. Such patients are also at risk for immune reconstitution inflammatory syndrome (IRIS) [<a href="#rid30">30-32</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pregnancy &gt;18 weeks has been associated with large (up to 6 cm<sup>2</sup>), exophytic, "cauliflower-like" CL lesions [<a href="#rid33">33,34</a>]. Obesity has also been associated with this finding [<a href="#rid35">35</a>].</p><p></p><p class="headingAnchor" id="H83446552"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H1961629"><span class="h2">Clinical approach</span><span class="headingEndMark"> — </span>The diagnosis of CL should be considered in patients with one or more chronic skin lesions and a history of exposure in an area where leishmaniasis is endemic [<a href="#rid36">36</a>]. Definitive diagnosis requires demonstration of the parasite in a clinical specimen (usually skin) by histology, culture, or molecular analysis via polymerase chain reaction (PCR). To maximize diagnostic yield, ideally all three diagnostic tests are warranted on the initial sample if feasible. If not all tests can be performed, then histology and PCR may provide sufficient information. Parasitologic diagnosis to the level of the <em>Leishmania</em> species should be pursued, since this information may influence determination of treatment [<a href="#rid1">1</a>]. Metagenomic next-generation sequencing (NGS) is also used for diagnosis [<a href="#rid37">37,38</a>].</p><p>Reference laboratory support is available; laboratories should be contacted before diagnostic samples are obtained to obtain instructions and transport media. In the United States, the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fdpdx%2Fdiagnosticprocedures%2Findex.html&amp;token=mo9Lat0niAV4dvPFFnbzjpkE3EXHe628SqhnlskGKON%2B18VyvIK5jjjU5QfrIyESNLAMtAkYNu6bxcxVBeq5Bw%3D%3D&amp;TOPIC_ID=5689" target="_blank">Centers for Disease Control and Prevention</a> (CDC) offers diagnostic services (email <a class="__cf_email__" data-cfemail="abdbcad9cad8c2dfced8c7cac9ebc8cfc885ccc4dd" href="/cdn-cgi/l/email-protection">[email protected]</a>). The CDC Parasitic Disease Public Inquiries may be contacted at 404-718-4745 (email <a class="__cf_email__" data-cfemail="c4809480bc84a7a0a7eaa3abb2" href="/cdn-cgi/l/email-protection">[email protected]</a>). The University of Washington Molecular Diagnosis Microbiology Section offers molecular testing for genus and species identification (email <a class="__cf_email__" data-cfemail="a5c8cac9c8ccc6c1dde5d0d28bc0c1d0" href="/cdn-cgi/l/email-protection">[email protected]</a>). The Walter Reed Army <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwrair.health.mil%2F&amp;token=rsW5TO5aDnKfmFE1NIdTJuFilhyAu5pL89RL94aVow7Y%2Bhf7M3mVJorrvLhq0swa&amp;TOPIC_ID=5689" target="_blank">Institute of Research</a> also provides diagnostic services for military and veteran patients and may be contacted at 240-595-7353. In Canada, the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.mcgill.ca%2Ftropmed%2Fnrcp&amp;token=5yLNPmHjkOhvnhOBCCm6DGcfBnwNVIU0L6NTgYz3pnI6BF6yMnNF61jZgY7Wq%2FCc&amp;TOPIC_ID=5689" target="_blank">National Reference Centre for Parasitology</a> offers diagnostic support.</p><p class="headingAnchor" id="H16816298"><span class="h3">Clinical history</span><span class="headingEndMark"> — </span>The clinical history should include an explicit travel history as well as questioning whether fellow travelers have developed similar lesions. Patients should be asked to comment on the duration of the skin lesions, whether they are painful (not typical of leishmaniasis), and whether they have progressed or improved. The history should also elicit the presence of nasal symptoms, comorbid medical conditions, prior treatment, and concurrent medications (particularly immunosuppressing ones) [<a href="#rid1">1</a>]. In addition, ascertaining the patient's level of concern about the skin lesions can be helpful for guiding treatment decisions.</p><p class="headingAnchor" id="H16816304"><span class="h3">Physical examination</span><span class="headingEndMark"> — </span>Physical examination should include a complete skin examination and careful evaluation of the anterior nares, septum, and oropharynx. Palpate along the lymphatic chains cephalad to lesions for subcutaneous nodules, gently palpate the lesion for tenderness and induration, and check for regionally draining lymph node enlargement. It can be helpful to measure and obtain photographs of skin lesions to assess progress over time. </p><p>Referral to a specialist for endoscopic otorhinolaryngologic examination is reasonable for patients with risk for mucosal leishmaniasis (such as those with epidemiologic exposure in South America) who have symptoms and/or signs of mucosal involvement or who have no symptoms or signs but thorough nasopharyngeal examination is not possible.</p><p class="headingAnchor" id="H83446560"><span class="h2">Specimen collection</span><span class="headingEndMark"> — </span>Specimens should be collected from lesions that appear active and ulcerative, without evidence of secondary infection [<a href="#rid1">1</a>]. The lesion should be cleaned gently with soap and water or povidone-iodine and then washed with <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a>; residual iodine and/or ethanol should be avoided if culture is planned. Remove any hyperkeratotic eschar. The base and margins of ulcerative lesions should be scraped gently with a sterile scalpel blade or lancet or brushed with a cytology brush. Touch impressions using tape or a glass slide touched to the ulcer may also provide diagnostic samples. The tissue collected should be submitted for histology, culture, and PCR.</p><p>Nodular lesions, plaque-like lesions, and lesions on the face (or other sensitive areas) may be sampled via injection and withdrawal of small amounts of nonbacteriostatic normal <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> at three to five sites. Some perform the aspiration without saline and obtain a tiny drop of aspirate in the hub of a 1 mL syringe, using a fine needle with rotary motion in lesion border. The aspirate may be submitted for culture and PCR. An alternative technique for sample collection consists of skin snips of the indurated margins of a lesion.</p><p>A full-thickness punch biopsy of the skin (4 to 5 mm) allows evaluation of histology and cellular response; it may also be submitted for culture to evaluate for leishmaniasis, acid-fast mycobacteria, and fungi. The preferred site for skin biopsy is the raised border of an ulcerative lesion  (<a class="graphic graphic_picture graphicRef86992" href="/z/d/graphic/86992.html" rel="external">picture 3</a>). Following biopsy, the sample should be gently blotted and then touched to a clean glass slide for multiple "touch prep" smears (see <a class="local">'Histopathology'</a> below). Excisional biopsies of skin lesions are not appropriate as recurrence may be seen along the suture line.</p><p class="headingAnchor" id="H1961071"><span class="h2">Diagnostic tools</span><span class="headingEndMark"> — </span>Diagnostic methods include visualization of the characteristic amastigote in smears or tissue (histopathology), parasite isolation by in vitro culture, and molecular detection of parasite DNA [<a href="#rid1">1</a>]. It is reasonable to pursue multiple diagnostic approaches to maximize the likelihood of a positive result, in conjunction with the expertise of a reference laboratory. Molecular amplification assays are the most sensitive tests available for diagnosis of CL (see <a class="local">'Molecular techniques'</a> below).</p><p class="headingAnchor" id="H83446574"><span class="h3">Histopathology</span><span class="headingEndMark"> — </span>The <em>Leishmania</em> amastigote is an oval to round organism 1.5 to 4.0 microns in diameter with a distinct cell membrane, cytoplasm, internal nucleus, and rod-shaped kinetoplast containing mitochondrial DNA  (<a class="graphic graphic_picture graphicRef86989" href="/z/d/graphic/86989.html" rel="external">picture 5</a>). Visualization of the kinetoplast is essential for a histologic diagnosis. This may require viewing several different sections in fixed tissue samples. Giemsa staining is typically used; with this stain, the cytoplasm is blue, the nucleus violet-blue, and the kinetoplast red to violet (a critical diagnostic characteristic). These findings may be observed on histology or touch prep smears.</p><p>A tissue Gram stain can be useful to highlight the kinetoplast in tissue samples, although hematoxylin and eosin staining is usually sufficient. Under oil immersion (100x), the parasites are found in macrophages in the upper dermis and are often surrounded by dermal chronic inflammation with lymphocytes, macrophages, plasma cells, and sometimes necrotizing granulomas. Organisms may be scarce in chronic lesions such as leishmaniasis recidivans (LR) and <em>L.V. braziliensis</em> infections.</p><p class="headingAnchor" id="H83446586"><span class="h3">Culture</span><span class="headingEndMark"> — </span>In appropriate culture media, tissue amastigotes may be converted to promastigotes. In one study including 202 skin lesions comparing diagnostic methods for CL in Peru, culture and smear were less useful for skin lesions of a duration &lt;3 months or &gt;12 months or for nonulcerative lesions [<a href="#rid39">39</a>].</p><p>Typical liquid media consists of Schneider's drosophila media supplemented with calf serum, or Novy, MacNeal, Nicolle (NNN) media. <em>Leishmania</em> grows best at 26°C; the rate of growth depends on the number of parasites in the tissue, species growth characteristics, and absence of secondary bacterial contamination from the skin (which can overgrow the culture).</p><p>Expansion of the parasite in culture permits speciation using isoenzyme electrophoretic patterns or molecular techniques [<a href="#rid40">40,41</a>]. Direct staining of cultured parasites or tissues with monoclonal antibodies can also be performed in some laboratories. These methods are slow since they require growth of the promastigote <em>Leishmania</em> form, and therefore species identification is not always available in a clinically useful timeframe. Molecular species identification is faster but less well-studied. Matrix-assisted laser desorption/ionization (MALDI) is a more rapid method that correlates well with conventional multilocus sequence typing, but it still requires an initial parasite expansion in culture step [<a href="#rid42">42</a>].</p><p>Culture for acid-fast bacilli and fungi may also be pursued to evaluate potential alternative diagnoses.</p><p class="headingAnchor" id="H83446605"><span class="h3">Molecular techniques</span><span class="headingEndMark"> — </span>Polymerase chain reaction is one of the most sensitive diagnostic tests for CL. High-performance characteristics have been reported compared with histology, culture, and smear [<a href="#rid39">39,43</a>]. It is important to note that PCR targets and assays vary. In one study including 202 skin lesions comparing diagnostic methods for CL in Peru, PCR had the greatest sensitivity irrespective of lesion characteristics [<a href="#rid39">39</a>]. False-negative results can occur due to technical issues or inhibitors in the sample.</p><p>The sensitivity and specificity of the SMART Leish PCR for the genus assay are 99 and 67 percent, respectively. The genus real-time PCR (RT-PCR) can detect at least four genome copies of <em>Leishmania </em>DNA [<a href="#rid44">44</a>]. The sensitivity and specificity of the SMART Leish-<em>L. major</em> assay for the species assay are 95 and 91 percent, respectively. RT-PCR has also been used for identification of <em>Leishmania</em> species [<a href="#rid45">45,46</a>].</p><p><em>Leishmania</em> DNA has been detected in scars of New World clinically-healed lesions years following treatment [<a href="#rid47">47-49</a>].</p><p class="headingAnchor" id="H1961389"><span class="h2">Other assays</span></p><p class="headingAnchor" id="H83446613"><span class="h3">Serology</span><span class="headingEndMark"> — </span>There is no clinical role for commercially available serology in the diagnosis of CL; the sensitivity and specificity are variable, and antibody levels are generally low. Most serologic assays cannot reliably distinguish between present and past infection. The sensitivity of serology may be higher in the setting of mucosal leishmaniasis (ML), and antibodies may decrease after treatment [<a href="#rid50">50</a>].</p><p>Serologic tests for visceral leishmaniasis can be cross-reactive in the setting of CL; these include the rK39 antibody test, such as the KalazarDetect rapid test and enzyme-linked immunosorbent assay [<a href="#rid51">51</a>].</p><p class="headingAnchor" id="H83446621"><span class="h3">Skin test</span><span class="headingEndMark"> — </span>The Montenegro or Leishmaniasis skin test has been evaluated in research studies and is used in South America, though no preparation has been approved for human use in the United States. The test consists of intradermal injection of killed promastigotes; it is positive in 82 to 89 percent of cases of localized CL [<a href="#rid52">52</a>]. The test is read 48 or 72 hours after intradermal injection; ≥5 mm induration is considered positive. The test cannot distinguish between active and resolved infection.</p><p>An interferon-gamma release assay for leishmaniasis has been developed for epidemiologic purposes but is not commercially available [<a href="#rid53">53</a>].</p><p class="headingAnchor" id="H5388869"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Conditions that may mimic CL are summarized below; in general, the diagnoses are distinguished by histopathology and culture.</p><p class="bulletIndent1"><span class="glyph">●</span>Fungal infection – A number of fungal infections present with cutaneous lesions resembling leishmaniasis; these include histoplasmosis and coccidioidomycosis. (See  <a class="medical medical_review" href="/z/d/html/2455.html" rel="external">"Pathogenesis and clinical manifestations of disseminated histoplasmosis"</a> and  <a class="medical medical_review" href="/z/d/html/2460.html" rel="external">"Primary pulmonary coccidioidal infection"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sporotrichosis occurs following cutaneous inoculation and presents with lymphocutaneous spread; in rare cases, pulmonary involvement may be observed. (See  <a class="medical medical_review" href="/z/d/html/2457.html" rel="external">"Clinical features and diagnosis of sporotrichosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mycobacterial infection – Cutaneous tuberculosis and atypical mycobacterial infection may present with skin lesions resembling CL. (See  <a class="medical medical_review" href="/z/d/html/15866.html" rel="external">"Cutaneous manifestations of tuberculosis"</a> and  <a class="medical medical_review" href="/z/d/html/5342.html" rel="external">"Overview of nontuberculous mycobacterial infections"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Leprosy – The dermatological manifestations of leprosy may overlap with the array of manifestations that occur in CL. Neuropathy occurs in the setting of leprosy but not in the setting of CL. (See  <a class="medical medical_review" href="/z/d/html/5348.html" rel="external">"Leprosy: Epidemiology, microbiology, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Skin cancer – Leishmaniasis can mimic the appearance of squamous cell carcinoma; these are distinguished by histopathology. (See  <a class="medical medical_review" href="/z/d/html/16225.html" rel="external">"Cutaneous squamous cell carcinoma (cSCC): Clinical features and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H442497474"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/127440.html" rel="external">"Society guideline links: Leishmaniasis"</a>.)</p><p class="headingAnchor" id="H1961886"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations </strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><em>Leishmania</em> causes a spectrum of cutaneous disease. Mucosal leishmaniasis (ML) and leishmaniasis recidivans (LR) are caused by oligoparasitic disease associated with a marked cellular immune response. Diffuse cutaneous leishmaniasis (DCL) is caused by polyparasitic disease with a predominance of parasitized macrophages and no granulomatous inflammation. The center of the spectrum consists of localized cutaneous leishmaniasis (LCL), which is the most common clinical presentation. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>LCL consists of cutaneous lesions on exposed areas of the skin. It begins as a pink-colored papule that enlarges and develops into a nodule or plaque-like lesion (often with central softening), leading to a painless ulceration with an indurated border  (<a class="graphic graphic_picture graphicRef64620" href="/z/d/graphic/64620.html" rel="external">picture 1</a>). In Old World cutaneous leishmaniasis (CL), the ulcer is often covered with a hyperkeratotic eschar  (<a class="graphic graphic_picture graphicRef87207" href="/z/d/graphic/87207.html" rel="external">picture 2</a>). In New World CL, the ulcer may be covered with thick white-yellow fibrinous material  (<a class="graphic graphic_picture graphicRef86992" href="/z/d/graphic/86992.html" rel="external">picture 3</a>). (See <a class="local">'Localized cutaneous leishmaniasis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with immunosuppressing conditions are at increased risk for more severe CL. These groups include patients on chronic corticosteroids, biologic modulators, or other immunosuppressive drugs, organ transplant recipients, pregnant patients, and patients with HIV/acquired immunodeficiency syndrome (AIDS). (See <a class="local">'CL in immunocompromised hosts'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis – </strong>The diagnosis of CL should be considered in patients with one or more chronic, usually painless, skin lesions and a history of exposure in an area where leishmaniasis is endemic. Definitive diagnosis requires demonstration of the parasite in a clinical specimen (usually skin) by histology, culture, or molecular analysis via polymerase chain reaction (PCR). Parasitologic diagnosis to the level of the <em>Leishmania</em> species should be pursued if feasible, since this information may influence determination of treatment. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="headingAnchor" id="H13572023"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Karin Leder, MBBS, FRACP, PhD, MPH, DTMH and Peter F Weller, MD, MACP, who contributed to an earlier version of this topic review.</p><p>The content and views expressed in this publication are the sole responsibility of the author and do not necessarily reflect the views or policies of the Department of Defense or the US Government. Mention of trade names, commercial products, or organizations does not imply endorsement by the US Government.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Aronson N, Herwaldt BL, Libman M, et al. Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis 2016; 63:e202.</a></li><li><a class="nounderline abstract_t">Melby PC. Experimental leishmaniasis in humans: review. Rev Infect Dis 1991; 13:1009.</a></li><li><a class="nounderline abstract_t">Jones TC, Johnson WD Jr, Barretto AC, et al. Epidemiology of American cutaneous leishmaniasis due to Leishmania braziliensis braziliensis. J Infect Dis 1987; 156:73.</a></li><li><a class="nounderline abstract_t">Soto J, Gutiérrez P, Soto P, et al. Treatment of Bolivian Leishmania braziliensis Cutaneous and Mucosal Leishmaniasis. Am J Trop Med Hyg 2022; 106:1182.</a></li><li><a class="nounderline abstract_t">Follador I, Araújo C, Bacellar O, et al. Epidemiologic and immunologic findings for the subclinical form of Leishmania braziliensis infection. Clin Infect Dis 2002; 34:E54.</a></li><li><a class="nounderline abstract_t">Convit J, Ulrich M, Fernández CT, et al. The clinical and immunological spectrum of American cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 1993; 87:444.</a></li><li><a class="nounderline abstract_t">Dowlati Y. Cutaneous leishmaniasis: clinical aspect. Clin Dermatol 1996; 14:425.</a></li><li><a class="nounderline abstract_t">Sousa Ade Q, Parise ME, Pompeu MM, et al. Bubonic leishmaniasis: a common manifestation of Leishmania (Viannia) braziliensis infection in Ceara, Brazil. Am J Trop Med Hyg 1995; 53:380.</a></li><li><a class="nounderline abstract_t">Herwaldt BL, Arana BA, Navin TR. The natural history of cutaneous leishmaniasis in Guatemala. J Infect Dis 1992; 165:518.</a></li><li><a class="nounderline abstract_t">Barral A, Guerreiro J, Bomfim G, et al. Lymphadenopathy as the first sign of human cutaneous infection by Leishmania braziliensis. Am J Trop Med Hyg 1995; 53:256.</a></li><li><a class="nounderline abstract_t">Cota GF, de Sousa MR, Fereguetti TO, et al. The Cure Rate after Placebo or No Therapy in American Cutaneous Leishmaniasis: A Systematic Review and Meta-Analysis. PLoS One 2016; 11:e0149697.</a></li><li><a class="nounderline abstract_t">Queiroz A, Sousa R, Heine C, et al. Association between an emerging disseminated form of leishmaniasis and Leishmania (Viannia) braziliensis strain polymorphisms. J Clin Microbiol 2012; 50:4028.</a></li><li><a class="nounderline abstract_t">Kubba R, Al-Gindan Y, el-Hassan AM, Omer AH. Clinical diagnosis of cutaneous leishmaniasis (oriental sore). J Am Acad Dermatol 1987; 16:1183.</a></li><li><a class="nounderline abstract_t">Marovich MA, Lira R, Shepard M, et al. Leishmaniasis recidivans recurrence after 43 years: a clinical and immunologic report after successful treatment. Clin Infect Dis 2001; 33:1076.</a></li><li><a class="nounderline abstract_t">van Henten S, Adriaensen W, Fikre H, et al. Cutaneous Leishmaniasis Due to Leishmania aethiopica. EClinicalMedicine 2018; 6:69.</a></li><li><a class="nounderline abstract_t">Develoux M, Diallo S, Dieng Y, et al. Diffuse cutaneous leishmaniasis due to Leishmania major in Senegal. Trans R Soc Trop Med Hyg 1996; 90:396.</a></li><li><a class="nounderline abstract_t">Guerra JA, Prestes SR, Silveira H, et al. Mucosal Leishmaniasis caused by Leishmania (Viannia) braziliensis and Leishmania (Viannia) guyanensis in the Brazilian Amazon. PLoS Negl Trop Dis 2011; 5:e980.</a></li><li><a class="nounderline abstract_t">Shirian S, Oryan A, Hatam GR, Daneshbod Y. Three Leishmania/L. species--L. infantum, L. major, L. tropica--as causative agents of mucosal leishmaniasis in Iran. Pathog Glob Health 2013; 107:267.</a></li><li><a class="nounderline abstract_t">el-Hassan AM, Zijlstra EE. Leishmaniasis in Sudan. Mucosal leishmaniasis. Trans R Soc Trop Med Hyg 2001; 95 Suppl 1:S19.</a></li><li><a class="nounderline abstract_t">Dimier-David L, David C, Muñoz M, et al. [Epidemiological, clinical and biological features of mucocutaneous leishmaniasis in Bolivia after a 221 patient sample]. Bull Soc Pathol Exot 1993; 86:106.</a></li><li><a class="nounderline abstract_t">Marsden PD. Mucosal leishmaniasis ("espundia" Escomel, 1911). Trans R Soc Trop Med Hyg 1986; 80:859.</a></li><li><a class="nounderline abstract_t">Boaventura VS, Santos CS, Cardoso CR, et al. Human mucosal leishmaniasis: neutrophils infiltrate areas of tissue damage that express high levels of Th17-related cytokines. Eur J Immunol 2010; 40:2830.</a></li><li><a class="nounderline abstract_t">Ives A, Ronet C, Prevel F, et al. Leishmania RNA virus controls the severity of mucocutaneous leishmaniasis. Science 2011; 331:775.</a></li><li><a class="nounderline abstract_t">Motta AC, Arruda D, Souza CS, Foss NT. Disseminated mucocutaneous leishmaniasis resulting from chronic use of corticosteroid. Int J Dermatol 2003; 42:703.</a></li><li><a class="nounderline abstract_t">Tuon FF, Sabbaga Amato V, Floeter-Winter LM, et al. Cutaneous leishmaniasis reactivation 2 years after treatment caused by systemic corticosteroids - first report. Int J Dermatol 2007; 46:628.</a></li><li><a class="nounderline abstract_t">Bogdan C. Leishmaniasis in rheumatology, haematology and oncology: epidemiological, immunological and clinical aspects and caveats. Ann Rheum Dis 2012; 71 Suppl 2:i60.</a></li><li><a class="nounderline abstract_t">Antinori S, Cascio A, Parravicini C, et al. Leishmaniasis among organ transplant recipients. Lancet Infect Dis 2008; 8:191.</a></li><li><a class="nounderline abstract_t">Mirzabeigi M, Farooq U, Baraniak S, et al. Reactivation of dormant cutaneous Leishmania infection in a kidney transplant patient. J Cutan Pathol 2006; 33:701.</a></li><li><a class="nounderline abstract_t">Mendonça MG, de Brito ME, Rodrigues EH, et al. Persistence of leishmania parasites in scars after clinical cure of American cutaneous leishmaniasis: is there a sterile cure? J Infect Dis 2004; 189:1018.</a></li><li><a class="nounderline abstract_t">Lindoso JA, Barbosa RN, Posada-Vergara MP, et al. Unusual manifestations of tegumentary leishmaniasis in AIDS patients from the New World. Br J Dermatol 2009; 160:311.</a></li><li><a class="nounderline abstract_t">Chrusciak-Talhari A, Ribeiro-Rodrigues R, Talhari C, et al. Tegumentary leishmaniasis as the cause of immune reconstitution inflammatory syndrome in a patient co-infected with human immunodeficiency virus and Leishmania guyanensis. Am J Trop Med Hyg 2009; 81:559.</a></li><li><a class="nounderline abstract_t">Couppié P, Clyti E, Sobesky M, et al. Comparative study of cutaneous leishmaniasis in human immunodeficiency virus (HIV)-infected patients and non-HIV-infected patients in French Guiana. Br J Dermatol 2004; 151:1165.</a></li><li><a class="nounderline abstract_t">Morgan DJ, Guimaraes LH, Machado PR, et al. Cutaneous leishmaniasis during pregnancy: exuberant lesions and potential fetal complications. Clin Infect Dis 2007; 45:478.</a></li><li><a class="nounderline abstract_t">Douba MD, Abbas O, Wali A, et al. Chronic cutaneous leishmaniasis, a great mimicker with various clinical presentations: 12 years experience from Aleppo. J Eur Acad Dermatol Venereol 2012; 26:1224.</a></li><li><a class="nounderline abstract_t">Lago T, Carvalho LP, Nascimento M, et al. Influence of Obesity on Clinical Manifestations and Response to Therapy in Cutaneous Leishmaniasis Caused by Leishmania braziliensis. Clin Infect Dis 2021; 73:1020.</a></li><li><a class="nounderline abstract_t">Aronson NE, Joya CA. Cutaneous Leishmaniasis: Updates in Diagnosis and Management. Infect Dis Clin North Am 2019; 33:101.</a></li><li><a class="nounderline abstract_t">Maia de Souza R, Ruedas Martins RC, Moyses Franco LA, et al. Identification of Leishmania species by next generation sequencing of hsp70 gene. Mol Cell Probes 2022; 61:101791.</a></li><li><a class="nounderline abstract_t">Han N, Yu J, Wang M, et al. The Value of Metagenomic Next-Generation Sequencing in Leishmaniasis Diagnosis: A Case Series and Literature Review. Open Forum Infect Dis 2022; 9:ofac511.</a></li><li><a class="nounderline abstract_t">Boggild AK, Ramos AP, Espinosa D, et al. Clinical and demographic stratification of test performance: a pooled analysis of five laboratory diagnostic methods for American cutaneous leishmaniasis. Am J Trop Med Hyg 2010; 83:345.</a></li><li><a class="nounderline abstract_t">Kreutzer RD, Christensen HA. Characterization of Leishmania spp. by isozyme electrophoresis. Am J Trop Med Hyg 1980; 29:199.</a></li><li><a class="nounderline abstract_t">de Almeida ME, Steurer FJ, Koru O, et al. Identification of Leishmania spp. by molecular amplification and DNA sequencing analysis of a fragment of rRNA internal transcribed spacer 2. J Clin Microbiol 2011; 49:3143.</a></li><li><a class="nounderline abstract_t">Mouri O, Morizot G, Van der Auwera G, et al. Easy identification of leishmania species by mass spectrometry. PLoS Negl Trop Dis 2014; 8:e2841.</a></li><li><a class="nounderline abstract_t">Reithinger R, Dujardin JC. Molecular diagnosis of leishmaniasis: current status and future applications. J Clin Microbiol 2007; 45:21.</a></li><li class="breakAll">The SMART Leish http:/www.accessdata.fda.gov/cdrh_docs/pdf8/K081868.pdf (Accessed on September 04, 2012).</li><li><a class="nounderline abstract_t">Antinori S, Calattini S, Piolini R, et al. Is real-time polymerase chain reaction (PCR) more useful than a conventional PCR for the clinical management of leishmaniasis? Am J Trop Med Hyg 2009; 81:46.</a></li><li><a class="nounderline abstract_t">Marfurt J, Niederwieser I, Makia ND, et al. Diagnostic genotyping of Old and New World Leishmania species by PCR-RFLP. Diagn Microbiol Infect Dis 2003; 46:115.</a></li><li><a class="nounderline abstract_t">Mendonça MG, de Brito ME, Rodrigues EH, et al. Persistence of leishmania parasites in scars after clinical cure of American cutaneous leishmaniasis: is there a sterile cure? J Infect Dis 2004; 189:1018.</a></li><li><a class="nounderline abstract_t">Schubach A, Marzochi MC, Cuzzi-Maya T, et al. Cutaneous scars in American tegumentary leishmaniasis patients: a site of Leishmania (Viannia) braziliensis persistence and viability eleven years after antimonial therapy and clinical cure. Am J Trop Med Hyg 1998; 58:824.</a></li><li><a class="nounderline abstract_t">Sghaier RM, Benhnini F, Guerfali FZ, et al. Healed Lesions of Human Cutaneous Leishmaniasis Caused By Leishmania major Do Not Shelter Persistent Residual Parasites. Front Cell Infect Microbiol 2022; 12:839216.</a></li><li><a class="nounderline abstract_t">Romero GA, de la Glória Orge Orge M, de Farias Guerra MV, et al. Antibody response in patients with cutaneous leishmaniasis infected by Leishmania (Viannia) braziliensis or Leishmania (Viannia) guyanensis in Brazil. Acta Trop 2005; 93:49.</a></li><li><a class="nounderline abstract_t">Hartzell JD, Aronson NE, Weina PJ, et al. Positive rK39 serologic assay results in US servicemen with cutaneous leishmaniasis. Am J Trop Med Hyg 2008; 79:843.</a></li><li><a class="nounderline abstract_t">Shaw JJ, Lainson R. Leishmaniasis in Brazil: X. Some observations of intradermal reactions to different trypanosomatid antigens of patients suffering from cutaneous and mucocutaneous leishmaniasis. Trans R Soc Trop Med Hyg 1975; 69:323.</a></li><li><a class="nounderline abstract_t">Turgay N, Balcioglu IC, Toz SO, et al. Quantiferon-Leishmania as an epidemiological tool for evaluating the exposure to Leishmania infection. Am J Trop Med Hyg 2010; 83:822.</a></li></ol></div><div id="topicVersionRevision">Topic 5689 Version 38.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27941151" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1962075" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Experimental leishmaniasis in humans: review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3598227" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Epidemiology of American cutaneous leishmaniasis due to Leishmania braziliensis braziliensis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35385826" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Treatment of Bolivian Leishmania braziliensis Cutaneous and Mucosal Leishmaniasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12015707" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Epidemiologic and immunologic findings for the subclinical form of Leishmania braziliensis infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8249076" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The clinical and immunological spectrum of American cutaneous leishmaniasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8889320" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Cutaneous leishmaniasis: clinical aspect.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7485690" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Bubonic leishmaniasis: a common manifestation of Leishmania (Viannia) braziliensis infection in Ceara, Brazil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1538157" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The natural history of cutaneous leishmaniasis in Guatemala.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7573708" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Lymphadenopathy as the first sign of human cutaneous infection by Leishmania braziliensis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26894430" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The Cure Rate after Placebo or No Therapy in American Cutaneous Leishmaniasis: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23035200" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Association between an emerging disseminated form of leishmaniasis and Leishmania (Viannia) braziliensis strain polymorphisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3597860" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Clinical diagnosis of cutaneous leishmaniasis (oriental sore).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11528583" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Leishmaniasis recidivans recurrence after 43 years: a clinical and immunologic report after successful treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31193672" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Cutaneous Leishmaniasis Due to Leishmania aethiopica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8882186" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Diffuse cutaneous leishmaniasis due to Leishmania major in Senegal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21408116" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Mucosal Leishmaniasis caused by Leishmania (Viannia) braziliensis and Leishmania (Viannia) guyanensis in the Brazilian Amazon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23916336" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Three Leishmania/L. species--L. infantum, L. major, L. tropica--as causative agents of mucosal leishmaniasis in Iran.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11370249" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Leishmaniasis in Sudan. Mucosal leishmaniasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8353467" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : [Epidemiological, clinical and biological features of mucocutaneous leishmaniasis in Bolivia after a 221 patient sample].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3037735" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Mucosal leishmaniasis ("espundia" Escomel, 1911).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20812234" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Human mucosal leishmaniasis: neutrophils infiltrate areas of tissue damage that express high levels of Th17-related cytokines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21311023" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Leishmania RNA virus controls the severity of mucocutaneous leishmaniasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12956682" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Disseminated mucocutaneous leishmaniasis resulting from chronic use of corticosteroid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17550567" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Cutaneous leishmaniasis reactivation 2 years after treatment caused by systemic corticosteroids - first report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22460140" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Leishmaniasis in rheumatology, haematology and oncology: epidemiological, immunological and clinical aspects and caveats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18291340" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Leishmaniasis among organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17026523" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Reactivation of dormant cutaneous Leishmania infection in a kidney transplant patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14999605" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Persistence of leishmania parasites in scars after clinical cure of American cutaneous leishmaniasis: is there a sterile cure?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19187345" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Unusual manifestations of tegumentary leishmaniasis in AIDS patients from the New World.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19815866" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Tegumentary leishmaniasis as the cause of immune reconstitution inflammatory syndrome in a patient co-infected with human immunodeficiency virus and Leishmania guyanensis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15606511" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Comparative study of cutaneous leishmaniasis in human immunodeficiency virus (HIV)-infected patients and non-HIV-infected patients in French Guiana.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17638198" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Cutaneous leishmaniasis during pregnancy: exuberant lesions and potential fetal complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21958339" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Chronic cutaneous leishmaniasis, a great mimicker with various clinical presentations: 12 years experience from Aleppo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33725723" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Influence of Obesity on Clinical Manifestations and Response to Therapy in Cutaneous Leishmaniasis Caused by Leishmania braziliensis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30712756" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Cutaneous Leishmaniasis: Updates in Diagnosis and Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35051596" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Identification of Leishmania species by next generation sequencing of hsp70 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36438623" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The Value of Metagenomic Next-Generation Sequencing in Leishmaniasis Diagnosis: A Case Series and Literature Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20682880" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Clinical and demographic stratification of test performance: a pooled analysis of five laboratory diagnostic methods for American cutaneous leishmaniasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7369438" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Characterization of Leishmania spp. by isozyme electrophoresis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21752983" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Identification of Leishmania spp. by molecular amplification and DNA sequencing analysis of a fragment of rRNA internal transcribed spacer 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24902030" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Easy identification of leishmania species by mass spectrometry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17093038" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Molecular diagnosis of leishmaniasis: current status and future applications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17093038" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Molecular diagnosis of leishmaniasis: current status and future applications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19556565" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Is real-time polymerase chain reaction (PCR) more useful than a conventional PCR for the clinical management of leishmaniasis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12812715" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Diagnostic genotyping of Old and New World Leishmania species by PCR-RFLP.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14999605" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Persistence of leishmania parasites in scars after clinical cure of American cutaneous leishmaniasis: is there a sterile cure?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9660473" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Cutaneous scars in American tegumentary leishmaniasis patients: a site of Leishmania (Viannia) braziliensis persistence and viability eleven years after antimonial therapy and clinical cure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35967864" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Healed Lesions of Human Cutaneous Leishmaniasis Caused By Leishmania major Do Not Shelter Persistent Residual Parasites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15589797" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Antibody response in patients with cutaneous leishmaniasis infected by Leishmania (Viannia) braziliensis or Leishmania (Viannia) guyanensis in Brazil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19052290" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Positive rK39 serologic assay results in US servicemen with cutaneous leishmaniasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/52214" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Leishmaniasis in Brazil: X. Some observations of intradermal reactions to different trypanosomatid antigens of patients suffering from cutaneous and mucocutaneous leishmaniasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20889872" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Quantiferon-Leishmania as an epidemiological tool for evaluating the exposure to Leishmania infection.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
